- Trials with a EudraCT protocol (26)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6)
![](img/info.png)
These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006). | |
Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records. |
Study title: Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):428-32. Epub 2006 Jan 11. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Wit M, Buchert R, Clausen M, Mautner VF. |
Active substance: FLUDEOXYGLUCOSE |
Study summary document link (including results): |
View full study record |
Document reference: 28091 |
Study title: WIDEMANN B. Novel Drugs for Children With Cancer /Neurofibromatosis. 2001. Crisp Data Base National Institutes of Health. 2003. WIDEMANN B. Novel Drugs for Children With Cancer /Neurofibromatosis. 2001. Crisp Data Base National Institutes of Health. 2003. |
Active substance: RALTITREXED |
Study summary document link (including results): |
View full study record |
Document reference: 35267 |
Study title: MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis; Chateil JF; Br. J. Radiol.; 2001 vol.74 p.24-31MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis; Chateil JF; Br. J. Radiol.; 2001 vol.74 p.24-31 |
Active substance: GADOTERIC ACID |
Study summary document link (including results): |
View full study record |
Document reference: 28859 |
Study title: Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Wit M, et al.. Epub 2006 Jan 11. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. [brenner-2006]Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):428-32. Brenner W 2006 |
Active substance: Steripet |
Study summary document link (including results): 2011-09 GE response Template List of published articles.doc |
View full study record |
Document reference: 48635 |
Study title: Clin Nucl Med. 1999 Jun;24(6):435-9. Tc-99m DTPA used as reference imaging to evaluate the distribution of other tumor-seeking tracers in tumors associated with neurofibromatosis. Suga K, Hirabayashi A, Kishimoto K, Kume N, Matsumoto T, Matsunaga N. Clin Nucl Med. 1999 Jun;24(6):435-9. Tc-99m DTPA used as reference imaging to evaluate the distribution of other tumor-seeking tracers in tumors associated with neurofibromatosis. Suga K, Hirabayashi A, Kishimoto K, Kume N, Matsumoto T, Matsunaga N. |
Active substance: THALLIUM 201T1 CHLORIDE |
Study summary document link (including results): |
View full study record |
Document reference: 44556 |
Study title: Kloos RT, Rufini V, Gross MD, Shapiro B. Bone scans in neurofibromatosis: neurofibroma, plexiform neuroma and neurofibrosarcoma. J Nucl Med. 1996 Nov;37(11):1778-83. Kloos RT, Rufini V, Gross MD, Shapiro B. Bone scans in neurofibromatosis: neurofibroma, plexiform neuroma and neurofibrosarcoma. J Nucl Med. 1996 Nov;37(11):1778-83. |
Active substance: TECHNETIUM (99mTc) MEDRONIC ACID |
Study summary document link (including results): |
View full study record |
Document reference: 43558 |